Overcoming Persistent Hurdles in Oncology
At Sapience, we think boldly about the possibilities for treating cancer, providing new options for patients that address the disease where it forms. We are developing first-in-class peptide antagonists against the most elusive oncogenic and immune-modulating drug targets.
Advancing Intelligently-Designed Therapeutics
We are pioneering a new class of peptide antagonists called SPEARs™ (Stabilized Peptides Engineered Against Regulation). SPEARs hold the potential to combine the best properties of small molecules and antibodies in disrupting oncogenic and immune regulation – allowing us to address cancer at the source of disease. Our first clinical SPEAR, ST101, is currently in the Phase 2 portion of a Phase 1/2 study in patients with late stage solid tumors.
Recent News
Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023
Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors
Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day
Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer
Sapience Therapeutics to Participate in Upcoming Investor Conferences
Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy from Phase 2 Study in Recurrent Glioblastoma (GBM) at Society for Neuro-Oncology (SNO) Annual Meeting
Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy, Long-Term Exposure and Safety in Phase 1-2 at 34th EORTC-NCI-AACR Symposium
Sapience Therapeutics Announces Poster Presentation on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting